LIDDS has today launched a newly designed website that will better reflect the ongoing company activities and the NanoZolid® project development pipeline. At the same time the web address is changed to www.liddspharma.com
Welcome to the website!
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: firstname.lastname@example.org
Bengt Norvik, CFO, +46 (0)730 74 68 00, e-mail: email@example.com
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid® technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid® can be combined with both large and small pharmaceutical molecules, such as antibodies. The company’s most advance project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid® is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS AB. For more information, go to www.liddspharma.com.